John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 10,500 shares at $193.86 ($2.0M) on 2021-04-16, disclosed to the SEC on 2021-04-19.
Open-market sale of $2.0M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $189.97 | 1,100 | $209K | 10.3% |
| 2 | $190.70 | 1,500 | $286K | 14.1% |
| 3 | $191.85 | 681 | $131K | 6.5% |
| 4 | $191.85 | 681 | $131K | 6.5% |
| 5 | $192.85 | 926 | $179K | 8.8% |
| 6 | $192.85 | 926 |
| $179K |
| 8.8% |
| 7 | $193.86 | 1,600 | $310K | 15.3% |
| 8 | $194.83 | 1,393 | $271K | 13.4% |
| 9 | $194.83 | 1,393 | $271K | 13.4% |
| 10 | $195.74 | 300 | $59K | 2.9% |
| Total | $192.87 avg | 10,500 | $2.0M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |